Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI versus IV adebrelimab combined with bevacizumab and HAI-FOLFOX for first-line advanced unresectable hepatocellular carcinoma
ChiCTR2400092928Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab, bevacizumab and FOLFOX in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall response rate by RECIST v1.1. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
adebrelimabbevacizumabFOLFOX
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400092928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092928.